Orchard Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Orchard Therapeutics generated cash of -$75,987,000, which is more than the previous year. Cash used in financing activities reached the amount of -$693,000 last year. Net change in cash is therefore $12,461,000.
Cash Flow
| 2016 | -14.56M | -190K | 18.03M |
|---|---|---|---|
| 2017 | -32.48M | -1.55M | 115.69M |
| 2018 | -97.53M | -4.03M | 354.86M |
| 2019 | -166.13M | -309.35M | 157.45M |
| 2020 | -126.27M | 157.37M | 3.93M |
| 2021 | -125.09M | -32.16M | 158.06M |
| 2022 | -75.98M | 90.56M | -693K |
ORTX Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 60.17M | 59.40M | 23.31M | 339.68M | 89.85M | 3.49M | 970K |
Operating activities | |||||||
Net income | -150.66M | -144.58M | -151.97M | -163.42M | -230.49M | -39.74M | -19.08M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 2.74M | 2.32M | 2.00M | 1.67M | 1.19M | 302K | 6K |
Stock-based compensation expense | 16.01M | 22.53M | 27.96M | 19.42M | 6.76M | 1.01M | 204K |
| Deferred income tax benefit | 16.01M | 22.53M | 27.96M | 19.42M | 6.76M | 1.01M | 204K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -7.42M | -624K | 582K | 715K | -927K | 0 | 0 |
Inventories | 0 | -20.10M | -5.22M | -10.60M | 15.71M | 0 | 0 |
Accounts payable | 13.64M | -9.45M | -1.55M | -6.41M | 14.84M | 1.93M | 666K |
Cash generated by operating activities | -75.98M | -125.09M | -126.27M | -166.13M | -97.53M | -32.48M | -14.56M |
Investing activities | |||||||
Purchases Of Investments | -112.28M | -263.87M | -113.26M | -414.01M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -6.51M | -3.23M | -12.66M | -4.36M | -4.03M | -1.55M | -190K |
Acquisitions Net | 0 | 887K | 0 | 304.99M | 0 | 0 | 0 |
Cash generated by investing activities | 90.56M | -32.16M | 157.37M | -309.35M | -4.03M | -1.55M | -190K |
Financing activities | |||||||
Common Stock Issued | 0 | 154.13M | 0 | 130.27M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -19K | -392K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -693K | 158.06M | 3.93M | 157.45M | 354.86M | 115.69M | 18.03M |
Net Change In Cash | 12.46M | 777K | 36.08M | -316.36M | 249.82M | 86.35M | 2.52M |
Cash at end of period | 72.63M | 60.17M | 59.40M | 23.31M | 339.68M | 89.85M | 3.49M |
| Data source | Data source | Data source | Data source | Data source |